FIG. 4.

HTA for patients 4, 5, 7, and 9 for the HVR1 and ISDR. Pretreatment and posttreatment HVR1 and ISDR sequences were analyzed by HTA using the corresponding patient’s heterogeneous pretreatment PCR product as a radiolabeled probe. Lanes: P, ³³P-radiolabeled probe; Pr, Po, and BT, pretreatment, posttreatment, and breakthrough time points, respectively. Note that for the ISDR, two different-size PCR products were analyzed, one corresponding to the ISDR from genotype 1a-infected patients and the other corresponding to the ISDR from genotype 1b-infected patients.